Stockreport
Gilead Sciences Earnings Preview: What to Expect [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
commercializing innovative medicines that address serious unmet medical needs in areas such as HIV/AIDS, viral hepatitis, COVID-19, oncology, and inflammation. Gilead Sciences has a market cap of around $155 billion, reflecting its position as a significant player in the healthcare and biotechnology sectors. The company is set to announce its fiscal Q4 earnings results soon. Ahead of the event, analysts expect GILD to report a profit of $1.86 per share, down 2.1% from $1.90 per share in the year-ago quarter. The company surpassed Wall Street's bottom-line estimates in three of the past four quarters and missed on another occasion. Trump Speech, Earnings and Other Key Things to Watch this Week Dear Intel Stock Fans, Mark Your Calendars for January 22 As Apple Teams Up with Google on Siri AI Upgrades, Should You Buy AAPL Stock? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered righ
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Royal Bank Of Canada from $100.00 to $103.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Hopping Mad Over Drug Company Product Hopping [Forbes][Forbes]
- More
GILD
SEC Filings
SEC Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/15/26 - Form 144
- GILD's page on the SEC website
- More